Biological individuality and the new frontiers of immunological tolerance in hematopoietic stem cell transplantation.

The treatment of thrombotic thrombo-cytopenic purpura with exchange transfusions, plasma infusions, and plasma exchange. multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange. The thrombotic thrombocytopenic purpura and hemolyt-ic uremic syndromes: evaluation, management, and long-term out-et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients. al. Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Prognostic value of anti-ADAMTS13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS13 activity. Battaglioli T, et al. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomedi-ated diseases. domain of ADAMTS13 provide a common antigenic core required for binding of antibodies in patients with acquired TTP. subclass distribution of anti-ADAMTS13 antibod-ies in patients with acquired thrombotic thrombocytopenic purpura, et al. Nonneutralizing IgM and IgG antibodies to von Willebrand factor -cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura (TTP). The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura. al. Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura. Cardiac involvement in acute thrombotic thrombocy-topenic purpura: association with troponin T and IgG antibodies to ADAMTS 13. acquired thrombotic thrombocytopenic purpura: ADAMTS13 inhibitory autoantibodies in identical twins. al. HLA-DRB1*11: a strong risk factor for acquired severe ADAMTS13 deficiency-related idiopathic thrombotic thrombocy-topenic purpura in Caucasians. Human leukocyte antigen association in idiopathic thrombotic thrombocytopenic purpura: evidence for an immunogenetic link. et al. Efficiency of curative and prophylactic treatment with ritux-imab in ADAMTS13-deficient thrombotic thrombocytopenic purpu-ra: a study of 11 cases. Remission in acute refractory and relapsing thrombotic thrombocy-topenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. From the time of the first successful experiences of allo-geneic bone marrow transplantation, 1,2 and during the long previous history of failure, 3 it became clear that HLA-iden-tity/compatibility between donor and recipient was an essential condition for the success of the transplant. Such compatibility is constantly found …